Patients with concurrent T lymphocyte infiltration and programmed cell death-ligand 1 (PD-L1) expression in the tumor microenvironment are likely to benefit from programmed cell death protein 1 (PD-1)/PD-L1 inhibition. Here, PDCD1 is linked to neoplasm.